[Lacosamide in epilepsy]
Tapia López E, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A.
Record ID 32018001444
Spanish
Original Title:
Lacosamida en epilepsia
Authors' recommendations:
CONCLUSIONS
High-quality evidence indicates that the use of lacosamide as adjuvant therapy in patients with drug-resistant focal epilepsy versus placebo decreases approximately 20% the frequency of seizures and achieves an increased rate of absence of seizures; however, it is associated to adverse events such as dizziness, vomiting and diplopia.
High-quality evidence shows similar efficacy between lacosamide and carbamazepine as monotherapy in patients with the first episode of epilepsy after a six-month follow up.
The clinical practice guidelines surveyed recommend its use as a treatment alternative, especially in patients with drug-resistant focal epilepsy, when the treatment with at least two other drugs has failed or is not well tolerated. Health sponsors from the Colombia, Mexico, Australia and France public system and the American insurance company Aetna cover it for this indication.
No cost-effectiveness studies have been identified in Argentina.
Details
Project Status:
Completed
Year Published:
2018
URL for published report:
https://www.iecs.org.ar/home-ets/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Argentina
MeSH Terms
- Epilepsy
- Lacosamide
- Drug Therapy
Contact
Organisation Name:
Institute for Clinical Effectiveness and Health Policy
Contact Address:
Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name:
info@iecs.org.ar
Contact Email:
info@iecs.org.ar
Copyright:
Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.